Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04166396 · ClinicalTrials.gov registry record · Early Phase 1
Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT04166396 is a Early Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 8 participants.
The verdict
NCT04166396, a Early Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine if the use of antioxidant supplements impacts exercise intolerance in people with CF.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Resveratrol
- DRUG NR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2024-07-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04166396
The ClinicalTrials.gov registry entry for NCT04166396 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04166396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04166396 about?
NCT04166396 is a clinical study titled "Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis". The purpose of this research study is to examine if the use of antioxidant supplements impacts exercise intolerance in people with CF.
What is the current status of trial NCT04166396?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2020-02-17. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04166396?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resveratrol (DRUG), NR (DRUG).
Who is sponsoring clinical trial NCT04166396?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.